Guggenheim Maintains Buy on ProMIS Neurosciences, Lowers Price Target to $5
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Guggenheim analyst Eddie Hickman maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and lowers the price target from $6 to $5.
Guggenheim analyst Eddie Hickman maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and lowers the price target from $6 to $5.